| scholarly article | Q13442814 |
| P2093 | author name string | Ching-Jung Hsieh | |
| Feng-Chih Shen | |||
| P2860 | cites work | Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. | Q51497444 |
| DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. | Q52886014 | ||
| Beneficial Effects of PKF275-055, a Novel, Selective, Orally Bioavailable, Long-Acting Dipeptidyl Peptidase IV Inhibitor in Streptozotocin-Induced Diabetic Peripheral Neuropathy | Q58874367 | ||
| Prescribing patterns in primary health care in Taiwan | Q70886105 | ||
| Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials | Q94680556 | ||
| Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes | Q94702289 | ||
| Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 | ||
| Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 | ||
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
| Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes | Q33562235 | ||
| Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
| Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 | ||
| Clinical usefulness of the two-site Semmes-Weinstein monofilament test for detecting diabetic peripheral neuropathy | Q34658741 | ||
| The role of incretins in glucose homeostasis and diabetes treatment | Q34901533 | ||
| The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study | Q36001145 | ||
| Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes | Q36742067 | ||
| Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin | Q36773485 | ||
| The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes | Q36877514 | ||
| Retinal pigment epithelial cells express a functional receptor for glucagon-like peptide-1 (GLP-1). | Q37332471 | ||
| The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes | Q38152588 | ||
| Sitagliptin: a review of its use in patients with type 2 diabetes mellitus | Q38177173 | ||
| Sensitivity and specificity of digital retinal imaging for screening diabetic retinopathy | Q39786608 | ||
| A Comparative study of examination scores and quantitative sensory testing in diagnosis of diabetic polyneuropathy | Q40179505 | ||
| Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial | Q42999172 | ||
| Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study | Q43067803 | ||
| Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes | Q43087481 | ||
| Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes | Q43195702 | ||
| The tuning fork revisited | Q44225337 | ||
| Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies | Q44548336 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 1905-1911 | |
| P577 | publication date | 2014-11-07 | |
| P1433 | published in | Clinical Interventions in Aging | Q5133768 |
| P1476 | title | The durability of sitagliptin in elderly patients with type 2 diabetes | |
| P478 | volume | 9 |
| Q38664568 | Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: Rationale and evidences |
| Q38410465 | Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial |
| Q64975777 | Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus and comparison of hypoglycemic action of concomitant medications: a subanalysis of the JAMP study. |
| Q26749165 | Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives |
| Q37008619 | Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1. |
| Q47140737 | Renal Function During an Open-Label Prospective Observational Trial of Sitagliptin in Patients With Diabetes: A Sub-Analysis of the JAMP Study |
| Q38614486 | Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients |
| Q90395295 | Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea |
| Q35681641 | Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study |
Search more.